"Guangzhou Pharmaceutical Group and Huawei jointly established the AI intelligent body project for the creation of innovative drugs, which was selected for the Ministry of Industry and Information Technology's 'Collection of High-Value Application Cases of Artificial Intelligence'"

The reporter learned from the Guangzhou Pharmaceutical Group that the project "Research and Application of AI Intelligent Body Development Driven by Domestic Algorithm Power for New Drug Creation" jointly developed by Guangzhou Pharmaceutical Group's Guangzhou Digital Science, Huawei, and First Core Molecular has been selected in the latest release of the Ministry of Industry and Information Technology's "Collection of High-Value Scenarios of Artificial Intelligence Applications". It is the only project selected from the pharmaceutical industry in China in this case collection. It is reported that the project has completed concept verification testing and is expected to shorten the lead compound discovery cycle from 12-18 months to 1-3 months, doubling the efficiency of preclinical development.